Kymera Therapeutics, Inc. (KYMR) vs Vaxcyte, Inc. (PCVX)
A side-by-side comparison of Kymera Therapeutics, Inc. and Vaxcyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KYMR
Kymera Therapeutics, Inc.
$104.47HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
PCVX
Vaxcyte, Inc.
$66.19HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — KYMR vs PCVX
growth of $100 · dividends reinvested · last 6yKYMR +230.3% (+22.0%/yr)PCVX +35.7% (+5.2%/yr)KYMR compounded faster over this window
KYMR PCVX
KYMR vs PCVX: by the numbers
- •PCVX is the larger company ($9.56B vs $8.59B market cap).
- •Both run net losses; PCVX's is the smaller (0.00% vs -285.41% net margin).
Metrics side by side
Valuation
| Metric | KYMR | PCVX |
|---|---|---|
| P/S ratio | 81.85 | N/A |
| P/B ratio | 5.69 | 3.47 |
Profitability
| Metric | KYMR | PCVX |
|---|---|---|
| Gross margin | 101.98% | 0.00% |
| Operating margin | -891.33% | 0.00% |
| Net margin | -285.41% | 0.00% |
| ROE | -19.85% | -38.59% |
| ROIC | -22.30% | -40.65% |
Growth (annualized)
| Metric | KYMR | PCVX |
|---|---|---|
| Revenue CAGR (5Y) | 10.22% | N/A |
| Total return CAGR (5Y) | 12.31% | 25.08% |
Frequently asked
- How have KYMR and PCVX total returns compared?
- Over the past 5 years, KYMR delivered 12.31% and PCVX delivered 25.08% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.